Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-NUC trial: stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B
2013-004882-15Phase 4Completed
- Sponsor
- Leipzig University
- Start
- May 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of lamivudine, adefovir dipivoxil, telbivudine, entecavir and tenofovir in Chronic hepatitis B (CHB) (2 arms), sponsored by Leipzig University. Primary endpoint: Sustained HBsAg loss up to week 96. Started May 2014; status: completed.
02
Drugs
lamivudineadefovir dipivoxiltelbivudineentecavirtenofovir
03
Conditions
Chronic hepatitis B (CHB)
Beyond the preview
Go deeper on 2013-004882-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004882-15.